The recent landmark Phase III clinical trial with a VEGF-specific antibody suggests that antiangiogenic therapy must be combined with cytotoxic therapy for the treatment of solid tumors. However, there are no guidelines for optimal scheduling of these therapies. Here we show that VEGFR2 blockade creates a "normalization window"-a period during which combined radiation therapy gives the best outcome. This window is characterized by an increase in tumor oxygenation, which is known to enhance radiation response. During the normalization window, but not before or after it, VEGFR2 blockade increases pericyte coverage of brain tumor vessels via upregulation of Ang1 and degrades their pathologically thick basement membrane via MMP activation.
Introduction
disorganized, and leaky vasculature and by high levels of VEGF (Plate et al., 1992; Millauer et al., 1994) . Extensive hypoxia Attempts to combine antiangiogenic therapy with radiation thermakes this highly malignant tumor resistant to radiation therapy apy have produced inconsistent findings: some experimental (Rampling et al., 1994) . In theory, reducing or abolishing vascular studies have demonstrated an additive tumor growth delay, abnormalities by anti-VEGF therapy should "normalize" the tuothers have shown a stronger, synergistic effect (Teicher et al., mor vasculature and alleviate hypoxia ). On the other 1995; Mauceri et al., 1998; Lee et al., 2000; Kozin et al., 2001;  hand, extensive destruction of tumor vessels by antiangiogenic Wachsberger et al., 2003) , and one study showed a comprotherapy can also hinder the delivery of oxygen and drugs, as mised therapeutic response (Murata et al., 1997) . Moreover, reported in cases where the antiangiogenic agent TNP-470 was previous studies have disagreed on the order in which antiangiocombined with radiation (Murata et al., 1997) and chemotherapy genic and radiation therapies should be given (Gorski et al., (Ma et al., 2001) . It is therefore critical to determine how to 1998; Rofstad et al., 2003; Zips et al., 2003) . To design an combine these therapies optimally. optimum combination therapy, we must unravel the mechanism Here we characterize the time course of morphological, and timing of tumor vessel response to antiangiogenic agents functional, and molecular changes in the vasculature of orand use this knowledge to optimize the treatment schedule.
thotopic gliomas in response to treatment with DC101, a monoTumor vessels are structurally and functionally abnormal, clonal antibody against VEGFR2 (Flk-1), and the relationship with defective endothelium, basement membrane, and pericyte between these vascular changes, tumor hypoxia, and radiation coverage (Carmeliet and Jain, 2000; Dvorak, 2002) . These abresponse. We show that it is possible to normalize the morpholnormalities impair the delivery of oxygen and therapeutics (Jain, ogy and function of brain tumor vasculature for a period of time, 2003) . One extreme example is glioblastoma multiforme, an leading to transient improvements in tumor oxygenation and response to radiation therapy. We also provide novel insight invariably fatal brain tumor characterized by a dilated, tortuous, into the role of angiopoietin-1 and matrix metalloproteinases in the normalization process.
Results
Anti-VEGFR2 therapy produces a time window of greatly reduced tumor hypoxia, during which radiation therapy is most effective We conducted a systematic evaluation of five treatment schedules, using a combination of DC101 (a VEGFR2-specific monoclonal antibody) and ␥ radiation to treat human glioblastoma xenografts growing orthotopically in the mouse brain ( Figure  1A ). In patients, radiation (along with surgery) is the main treatment for these tumors. We found that, when used as a monotherapy, DC101 (given at 40 mg/kg on days 0, 3, and 6) produced a small, statistically insignificant tumor growth delay of ‫5.2ف‬ days, while radiation (three daily fractionated doses of 7 Gy each) significantly delayed the growth by ‫5.21ف‬ days. When DC101 was given in nonoptimal combinations with radiation (RT1, RT2, RT3, RT5), the combined therapy had no more than an additive effect. However, giving radiation therapy on days 4 to 6 after DC101 treatment began (RT4) produced a synergistic effect in which the tumor growth delay significantly exceeded the expected additive effect ( Figure 1A ).
Because hypoxia significantly decreases the efficacy of radiotherapy (Hall, 2000) and is typically severe in glioblastoma multiforme (Rampling et al., 1994) , we hypothesized that this synergy arises from a DC101-induced improvement in tumor oxygenation, which enhances the cytotoxic effect of radiation treatment. Indeed, the optimum time for radiation treatment coincided with the time of maximum tumor oxygenation: during DC101 treatment, tumor hypoxia began to drop on day 2, was almost abolished on day 5, and increased again by day 8 ( Figure  1B ). In contrast, apoptosis of tumor and vascular cells did not coincide with the optimum treatment schedule: the apoptotic level increased significantly on day 5 and remained the same on day 8. Even at these times, apoptosis was moderate and did not lower the cellular (nuclear) density in tumor sections synergistic during a "normalization window" when tumor hypoxia is greatly diminished (Table 1) . Thus, it is unlikely that increased tumor or vascular cell apoptosis after DC101 accounts for the reduced tumor A: Tumor growth delay of orthotopic U87 gliomas is shown for untreated controls (C), monotherapy with the VEGFR2-specific antibody DC101 (three hypoxia and the improved radiation response around day 5.
injections, three days apart), local radiation for three consecutive days (RT), and five different combination schedules where radiation was given before, Pericytes are recruited to existing tumor blood during, or after DC101 therapy (RT1-RT5; see diagram for schedules). The vessels during the normalization window, dashed lines show the range of the expected additive effect (EAE) of DC101 and radiation. *p Ͻ 0.05, compared to RT; ϩ p Ͻ 0.05, compared to EAE.
but not before or afterward B: Tumor hypoxia (pimonidazole staining, red) was severe in control tumors,
We set out to determine the mechanism by which VEGFR2 but decreased for a limited time during monotherapy with DC101. Hypoxia blockade transiently lowers hypoxia in glioma xenografts. We reached a minimum at day 5, and a partial relapse occurred at day 8.
have shown that VEGF blockade can normalize the vasculature *p Ͻ 0.05, compared to untreated control; ϩ p Ͻ 0.05, compared to rat IgGin transplanted (Yuan et al., 1996; Kadambi et al., 2001 ; Tong treated control (day 2); #p Ͻ 0.05, compared to day 2 after initiation of DC101 therapy.
et al., 2004) and spontaneous human (Willett et al., 2004) tumors, decreasing the density, diameter, and tortuosity of vessels and improving their integrity. It is possible that vascular normalization can enhance the effectiveness of radiotherapy or chemobut the time course of this change has not been determined to therapy by improving the delivery of oxygen and drugs, respecdate. We found that, during DC101 treatment, vessel coverage tively . We therefore asked whether the alleviation by closely associated pericytes remained low through day 1, of tumor hypoxia is due to the transient normalization of glioma increased markedly between days 2 and 5, and fell again by vessels by anti-VEGFR2 therapy. day 8 (Figure 2A) . Thus, the kinetics of pericyte coverage mirIt has recently been demonstrated, in both murine and hurored those of tumor hypoxia. man tumors, that VEGF signal blockade increases the fraction The mechanisms responsible for the increase in pericyte of vessels that are covered with closely attached perivascular cells (Tong et al., 2004; Willett et al., 2004; Inai et al., 2004) , coverage are largely unknown. It is widely assumed that this B: DC101 treatment reduced the diameter of enlarged tumor vessels, starting at day 2 of therapy. In contrast, vessel length density was not changed at day 2, but decreased progressively at later time points. Angiograms were obtained using dynamic multiphoton laser scanning microscopy in vivo (see Supplemental Figure S1 at http://www.cancercell.org/cgi/content/6/6/ 553/DC1/ for representative images and values). Scale bars, 100 m. *p Ͻ 0.05, compared to ratIgG treated control (2 days of treatment).
increase is due to the preferential pruning of pericyte-poor vessels (Benjamin et al., 1999) , but if this were the case, the increased coverage should be accompanied by a decrease in vessel length per unit volume of tumor tissue; this was not observed in our study. Two days after the initial DC101 injection, when pericyte coverage reached its peak, we found a significant decrease in the diameter of tumor vessels, consistent with our previous data (Yuan et al., 1996; Kadambi et al., 2001; Tong et al., 2004) , but there was no decrease in vessel length density in the treated mice compared to untreated controls or nonspecific IgG-treated controls (Figures 2A and 2B ). Furthermore, by day 8, extensive vascular regression had occurred ( Figure 2B and Supplemental Figure S1 at http://www.cancercell.org/cgi/ content/full/6/6/553/DC1/), but pericyte coverage had fallen to the control level ( Figure 2A ), suggesting that the pericyte-covered vessels enjoyed no long-term survival advantage. These results suggest that, rather than selectively pruning pericytepoor vessels, VEGFR2 blockade temporarily facilitates the recruitment of pericytes to tumor vessels.
Angiopoietin-1 upregulation in the tumor cells promotes pericyte recruitment to tumor vessels after VEGFR2 blockade
To investigate the molecular mechanisms of pericyte recruitment by VEGFR2 blockade, we used a cDNA microarray to examine the expression of 96 human and murine genes associated with angiogenesis and vessel maturation. At the time of peak pericyte coverage (day 2 after DC101 therapy), only two molecules were differentially regulated more than 3-fold: human angiopoietin-1 (Ang-1; 4.8-fold upregulation) and human Ephrin B2 (3.8-fold upregulation). Quantitative real-time PCR using species-specific primers confirmed only a nearly 3-fold increase in human Ang-1 transcripts at day 2, but not at day 8 (Table 2) . Furthermore, increased synthesis of Ang-1 mRNA by cancer cells resulted in increased deposition of Ang-1 protein in proximity to its receptor Tie2 on endothelial cells at days 2 and 5, but, again, not at day 1 or day 8 ( Figure 3A ). Ang-1 upregulation at day 5 of DC101 therapy was also confirmed by Western blot analysis of whole tumor lysates ( Figure 3B ). An effect of VEGF/ VEGFR2 signaling on the Ang-1/Tie2 pathway has not previously been shown. Because Ang-1 is known to be involved in pericyte recruitment (Stoeltzing et al., 2003; Jain, 2003) , our results suggest that Ang-1 mediates the DC101-induced recruitment of pericytes to tumor vessels. In order to confirm the causal role of Ang-1, we first used a Tie2-blocking antibody or peptide to block Ang-1/ Tie2 signaling. In the presence of Tie2 blockade, DC101 failed to increase vascular pericyte coverage, consistent with our hypothesis ( Figure 2A ). DC101 therapy also failed to decrease mean vascular diameter ( Figure 3C ) when Tie-2 was blocked. A second experiment confirmed that tumor cell-derived Ang-1 is indeed responsible for pericyte recruitment after VEGFR2 blockade: when U87 glioma cells were stably transfected with Ang-1 siRNA (siAng-1), these cells expressed ‫%05ف‬ less Ang-1 mRNA in vitro and ‫%09ف‬ less Ang-1 protein near blood vessels in vivo ( Figure 3A ). In siAng-1 tumors, DC101 therapy increased vascular Ang-1 protein deposition insufficiently: only levels similar to those in wild-type control tumors were reached ( Figure  3A) . Consequently, siAng-1 tumors revealed a greatly reduced Quantitative real-time PCR analysis of human and murine genes involved in vessel maturation and basement membrane synthesis. Tumors were dissected from controls (n ϭ 8), 2 days after DC101 treatment (n ϭ 8), or 8 days after DC101 treatment (n ϭ 3). Four candidate genes were chosen based on the results of cDNA microarray analysis: hAng-1 was upregulated 4.8-fold and hEphrin B2 3.8-fold, while mCD105 was downregulated 2.5-fold and mEphrin B2 2.6-fold. In addition, we analyzed additional genes, known to be involved in vascular maturation, that were below the detection limit of the cDNA microarray: human PDGF-B, mouse PDGFR␤, and mouse EphB4. The ratio of hAng-1 to mAng-2 was determined separately for each animal, and means are given for each group. Values represent relative gene expression normalized to ␤-actin. *p Ͻ 0.05, compared to controls; ϩ p Ͻ 0.05, compared to DC101 treated, day 2. m, murine; h, human.
pericyte recruitment to tumor vessels at day 2 of DC101 therapy ( Figure 2A ). Collectively, these data suggest that pericyte re- A: Ang-1 protein (red) colocalized with perfused vessels (green) 2 and 5 days after initiation of DC101 therapy. In contrast, low levels of Ang-1 near perfused vessels was observed in control tumors, at day 1 and at day 8 after initiation of DC101 therapy, and when Ang-1 protein production was blocked in tumor cells by siRNA transfection (siAng-1). B: Western blot analysis confirmed increased Ang-1 expression in whole tumor lysates at day 5. C: Treatment with an anti-Tie2 antibody (␣Tie2 AB) inhibited the DC101-induced decrease in mean vessel diameter after 2 days. D: Tie2 inhibition with an ␣Tie2 peptide also diminished tumor reoxygenation at day 5 of DC101 therapy. Scale bars, 100 m. *p Ͻ 0.05, compared to untreated control; ϩ p Ͻ 0.05, compared to rat-IgGtreated control (day 2); #p Ͻ 0.05, compared to day 2 after initiation of DC101 therapy.
cruitment by tumor cell-derived Ang-1 plays a critical role in the ported in other tumor models (Baluk et al., 2003) , and has also been observed in diabetes mellitus and neurodegenerative disnormalization of vessel diameter after VEGFR2 blockade.
Ang-1 is also known to reduce vascular permeability of the eases, where it was linked to impaired vascular function (Tsilibary, 2003; Farkas et al., 2000) . In addition, BM thickening is blood-brain barrier (Lee et al., 2003) . However, although we found that vascular permeability to albumin was reduced seen in human glioblastoma multiforme: a majority (18 out of 30) of glioblastoma patients show tumor vessels characterized throughout the entire course of DC101 treatment (Supplemental Figure S1F ), this reduction was independent of the kinetics of by a pathologically thick BM ( Figure 4B ). Ang-1 expression or pericyte coverage, which suggests that it was not mediated by Ang-1 exclusively.
VEGFR2 blockade degrades basement membrane
We finally sought to demonstrate that vascular stabilization via activation of matrix metalloproteinases induced by angiopoietin-1 indeed results in better tumor oxyBecause Tie-2 blockade did not affect the thinning of tumor genation after VEGFR2 blockade. When the Tie2 receptor was vessel BM, indicating that increased pericyte involvement was blocked, reduction in tumor hypoxia at day 5 was diminished not responsible ( Figure 5A ), we investigated the possibility that after DC101 therapy ( Figure 3D ), indicating a causal link between reduced production and/or increased degradation of BM comAng-1-mediated vascular normalization and vascular function.
ponents was responsible for the change in BM morphology. Indeed, the mRNA expression of murine collagen IV was reduced after DC101 treatment (Table 2) . However, increased The abnormally thick basement membrane of brain tumor vessels is reduced during activity of the matrix metalloproteinases (MMPs) -2 and -9, which can rapidly degrade collagen IV and other components the normalization window We also observed dramatic changes in the vascular basement of the BM, may be functionally more important. In contrast, MMP-9 was shown to be downregulated by inhibition of membrane (BM) 2 to 5 days after DC101 injection. Whereas vessels in control tumors had an aberrantly thick, multilayer BM VEGFR2 (Sweeney et al., 2002) or VEGFR1 (Hiratsuka et al., 2002) signaling in murine lung endothelial cells in vivo and (as indicated by collagen IV staining), DC101 treatment reduced BM thickness on days 2 and 5, and (to a lesser degree) on day in vitro. In U87 gliomas, we found that MMP-2 and -9 proteins were expressed around vessels at equivalent levels in control 8, but not on day 1 (Figure 4A ). Similar changes occurred in the other major BM components (laminin, entactin, perlecan). The and treated animals (not shown), so we investigated whether posttranslational MMP activation occurs after VEGFR2 block-BM is shared by endothelial cells and pericytes and is a major component of the vascular wall. BM thickening has been reade. Surprisingly, using in situ zymography, we discovered an 
A:
The vascular basement membrane (collagen IV staining, red) was thin and closely associated with perfused vessels (green) in normal brain, but appeared thickened, disorganized, and occasionally multilayered in control tumors. DC101 reduced the mean basement membrane thickness at day 2 and 5. This effect was not visible before day 2, and was diminished by day 8 of DC101 therapy. *p Ͻ 0.05, compared to untreated control; ϩ p Ͻ 0.05, compared to control treated with rat nonspecific IgG (day 2); #p Ͻ 0.05, compared to day 2 after initiation of DC101 therapy. B: A majority (18/30) of glioblastoma patients showed tumor vessels with a thickened basement membrane. Scale bars, 100 m.
increase in collagenase IV activity at the vascular wall 2 days Munn, 2000) : it has been shown to increase pericyte coverage, and several studies indicate that this process implies vessel after DC101 therapy ( Figure 5B ). Furthermore, coadministration maturation and improved vascular function (Hawighorst et al., of a broad-spectrum inhibitor of the matrix metalloproteinases 2002; Stoeltzing et al., 2003) . Furthermore, even in the complete (MMPs), GM6001, completely abolished the DC101-induced absence of mural cells, recombinant Ang-1 can restore a hierar-BM thinning ( Figure 5C ). chical vasculature and inhibit retinal edema and hemorrhage (Uemura et al., 2002) . It also reduces vascular permeability in Discussion the skin (Thurston et al., 1999) , tumors (Stoeltzing et al., 2003) , and an in vitro blood-brain barrier model by maturation of endoCollectively, these results demonstrate that VEGFR2 blockade thelial cells (Lee et al., 2003) . Consistent with these findings, can temporarily normalize tumor vessel structure (pericyte and the increased expression of the naturally occurring Ang-1 antagbasement membrane coverage), leading to improved vascular onist, Ang-2, in glioma vessels is associated with their destabilifunction (tumor oxygenation) and enhanced response to radiazation (Holash et al., 1999) and is negatively correlated with tion therapy. Figure 6A illustrates the time course of these pericyte coverage, both in human glioblastoma specimens changes, while the proposed underlying molecular mechanisms (Stratmann et al., 1998) and experimental gliomas (Koga et al., are summarized in Figure 6B .
2001). Here we show that an increase in the Ang-1/Ang-2 ratio Our findings suggest several important changes to the existwith activated Ang-1/Tie2 signaling after VEGFR2 blockade reing paradigm. Contrary to the view that the primary result of cruits pericytes to tumor vessels and subsequently reduces anti-VEGF treatment is to prune tumor vessels that are devoid their enlarged diameter, demonstrating a profound effect of this of pericytes (Benjamin et al., 1999) , we show that, during the phenomenon on the tumor vessel network. Therefore, Ang-1 normalization window in brain tumors, VEGFR2 blockade temupregulation acts synergistically with the direct effects of porarily recruits pericytes to blood vessels by activating Ang-1/ VEGFR2 blockade on endothelial cells to normalize brain tumor Tie2 signaling. These fortified vessels become more efficient, vessels. enhancing oxygen delivery to the tumor.
Ang-1 upregulation after VEGFR2 blockade is not specific Ang-1 has been implicated in facilitating interaction between for brain tumor vessels: in subcutaneously growing MCaIV endothelial cells and pericytes during angiogenesis (Jain, 2003) . mammary carcinomas, DC101 therapy likewise resulted in inOthers have shown that expression of Ang-1 is restricted to creased expression of Ang-1 and its vascular deposition (Supcancer cells in human glioblastoma multiforme (Stratmann et plemental Figure S2 ) at a time of increased pericyte coverage al., 1998) and glioma animal models (Holash et al., 1999) . Our (Tong et al., 2004) . However, neither Ang-1 expression nor periresults extend this finding, showing that Ang-1 protein produced cyte coverage was changed in normal vessels of the brain, by tumor cells is found mainly in the vicinity of vessels, where heart, and kidney during DC101 therapy (unpublished data), it is sequestered by its endothelial receptor Tie2. Ang-1 has indicating that Ang-1 upregulation after VEGFR2 blockade is specific for the tumor environment. well-defined, substantial effects on the vasculature (Jain and A: VEGFR2 blockade produces a time window of morphological and functional normalization of tumor vessels, which determines the tumor response to radiotherapy.
B: Mechanisms of tumor vessel normalization by DC101. (i) Control tumors
It has previously been shown that chronic overexpression are characterized by tortuous, dilated blood vessels that lack tight pericyte coverage and display a thickened, detached basement membrane. These of angiopoietin-1 starting during embryonic development invascular abnormalities occur in the presence of excessive VEGF/VEGFR2
creases the diameter of normal vessels (Thurston et al., 1999, signaling. (ii) Within two days, VEGFR2 blockade can normalize BM morphol-
2000), while transient Ang-1 overexpression in normal adult
ogy by activation of matrix metalloproteinases, increasing BM degradation.
vasculature (Thurston et al., 2000) or chronic Ang-1 overexpres- The mechanism by which Ang-1 is upregulated after required for full vascular normalization.
VEGFR2 inhibition remains unknown. Ang-1 protein (as detected by Western blot) was not changed in U87 cells in vitro after exposure to DC101, which makes a direct effect of DC101 on the tumor cells unlikely. Likewise, even though Ang-1 expresImproved oxygenation significantly overcompensated for this assumed radioprotection of endothelial cells by Ang-1, emphasion was increased after reoxygenation of cultured astrocytes (Song et al., 2002) , we could not confirm a change in Ang-1 sizing once again that oxygen status dominates other factors in determining the outcome of optimally combined therapy. protein in U87 glioma cells after 24 hr of hypoxia (0.5% oxygen) and at different time points of reoxygenation (data not shown).
The therapeutic gain achieved due to DC101 in the synergistic combination group RT4 is substantial-from a tumor We would therefore rather hypothesize that a paracrine mediator that binds to adjacent tumor cells is produced by endothelial growth delay of 12.5 days for radiation alone to 21.7 days for DC101ϩRT4. To achieve a 21.7-day growth delay with radiation cells after VEGFR2 blockade, which, in turn, increases their Ang-1 synthesis.
alone, we would need to increase its total dose from 21 to 35-38 Gy (Kozin et al., 2001 ). The fact that we saw such a substantial Our study provides evidence that severe abnormalities of the vascular basement membrane in glioma vessels are mediincrease in growth delay attests to the importance of tumor oxygenation for radiation therapy (Hall, 2000) . ated by VEGF signaling, since VEGFR2 blockade restores a thinner, more closely attached BM monolayer by increasing
The ability to measure tumor hypoxia in patients using noninvasive imaging techniques may enable clinicians to optimize collagen IV degradation by MMPs. The thick, disorganized basement membrane in untreated tumors likely contributes to imthe combination of anti-VEGF treatment with radiation therapy. Similar optimization strategies may also improve response to paired vascular function. It is plausible that a thickened sheet of extracellular matrix can affect the extravasation of oxygen, chemotherapy. It is tempting to speculate that, if the time course of vascular changes induced by VEGF blockade is taken into drugs, and nutrients (Tsilibary, 2003; Farkas et al., 2000) . In contrast, subcutaneously implanted mammary carcinomas account, one might achieve a survival advantage greater than the 5 months seen in the recent landmark clinical trial of combihave incomplete vascular BM coverage. In these tumors, VEGFR2 blockade increases BM coverage to near normal levels nation therapy (Hurwitz et al., 2004) . (Tong et al., 2004) . These seemingly contradictory findings illus-
Experimental procedures
trate that the phenotype of the tumor vessel BM is dependent on the local microenvironment. In both cases, VEGFR2 blockade Animal model and cell lines appears to alter BM homeostasis, shifting the rates of BM synWe implanted cranial windows into 8-to 10-week-old male nude mice as thesis and degradation to produce a more normal BM phenopreviously described (Yuan et al., 1994) . After one week, we implanted small type. Our study not only sheds light on the mechanism of BM (0.2-0.3 mm diameter) fragments of U87 glioma tumors superficially into the cerebral cortex under the cranial window at a depth of approximately 0.4 thickening in gliomas but also demonstrates that it can be normm. Animals were anesthetized with ketamine/xylazine (100/10 mg/kg, i.m.) malized by disrupting the VEGF pathway.
for all experimental procedures. Intravenous injections were performed using Most importantly, our results alleviate the concern that, by a lateral tail vein. All cell lines were maintained in DMEM medium with 10% destroying blood vessels, antiangiogenic therapy will invariably FBS. To obtain a stable short interfering hairpin RNA (siRNA) construct for increase tumor hypoxia, leading to an increased resistance to silencing the angiopoietin-1 gene (siAng-1), we used oligos 5Ј-GAT CCG radiation and increased metastatic potential (Bottaro and Liotta, NLLMAAS (Tournaire et al., 2004) stereotactically into the tumor. For inhibitime PCR, we quantified mRNA levels of various candidate molecules that were identified by cDNA array analysis. Lux fluorogenic primers (Invitrogen) tion of MMPs, mice were injected i.p. with 150 g of the broad spectrum MMP inhibitor GM 6001 (Ryss Lab). All agents were given 30 min after the specific for the mouse or human isoform of each mRNA species were designed using Lux Online Primer Software (Invitrogen; primer sequences availmice received either DC101 or nonspecific rat IgG control antibody, and the animals were sacrificed 2 or 5 days later. able on request). Quantitative RT-PCRs were performed on the ABI 7700 sequence detection system (Applied Biosystems). All experiments were performed in duplicate, and a standard curve for the specific cDNA of interest Angiography by multiphoton laser scanning microscopy (MPLSM) was run with every PCR reaction; amounts of cDNA are expressed relative and microvascular permeability measurement to this standard curve. Final quantification of each cDNA sample was relative In vivo MPLSM angiography of glioblastoma vessels was performed after to human or mouse ␤-actin according to the manufacturer's instructions i.v. injection of 0.1 ml 10 mg/ml FITC-Dextran (2M MW, Sigma) as described (Applied Biosystems). previously (Brown et al., 2001) . For each tumor, four adjacent images repreAng-1 protein expression was determined by Western blot analysis. senting tumor vessels Ϫ75 to Ϫ200 m below the brain surface were obTotal protein from tumor xenografts was extracted in RIPA buffer, and 30 tained through the cranial window at day Ϫ1, and the same regions identified g of protein was separated on a 10% SDS-PAGE gel, transferred to PVDF by using landmarks of the overlaying pial vasculature were recorded at days membrane, and incubated with anti-Ang1 antibody (1:1000, 4ЊC overnight). 1, 2, 5, and/or 8 (n ϭ 4 animals per group). Vessel length density, diameter, Ang1 was visualized using the enhanced chemiluminescence kit (Amerand volume were calculated for each vessel using NIH IMAGE 1.63 software sham). (http://rsb.info.nih.gov/nih-image/), and means are expressed relative to the value that was obtained in the same tumor region one day before initiation Statistical analysis of treatment. The microvascular permeability to albumin was measured as Data are expressed as mean Ϯ SEM. The principal statistical test was the previously described (Yuan et al., 1996) .
Student's t test (two tailed). p Ͻ 0.05 was considered to be statistically significant.
Histology and immunostaining
Tumor-bearing mice were injected i.v. with biotinylated lectin (Vector LaboraAcknowledgments tories), heart-perfused with 4% paraformaldehyde, and blood vessels were stained with a Streptavidin-conjugated fluorochrome (Alexa 488 or Alexa Supported by the Goldhirsh Foundation and the National Cancer Institute. 647; Molecular Probes). Thin (10 m) or thick (100 m) sections were incu-F.W. is a fellow of the Deutsche Forschungsgemeinschaft, Emmy-Noether bated at 4ЊC overnight with one of the following antibodies: rabbit antiProgramm. We thank Sylvie Roberge for her excellent technical assistance, collagen IV (1:2000; Chemicon), rabbit anti-NG2 (1:1000; Chemicon), or goat and Yves Boucher, Dan Duda, Tim Padera, and Herman D. Suit for helpful anti-Ang-1 (1:100; Santa Cruz), and subsequently with Cy3-conjugated seccomments on the manuscript. The monoclonal antibody DC101 was generondary antibodies (1:200, Jackson ImmunoResearch). Apoptosis staining ated by ImClone Systems, of which D.J.H. is an employee. The remaining was performed by the indirect TUNEL method using the ApopTag Red authors have no financial interest related to this work. In Situ Apoptosis Detection Kit (Chemicon) according to manufacturers' instructions. To detect tumor hypoxia, 60 mg/kg pimonidazole was injected i.v. 1 hr before brains were rapidly frozen at Ϫ80ЊC. The Hypoxyprobe-1 Kit (Chemicon) was used to detect pimonidazole-protein adducts in 2 brain maximum intensity projections were generated, and calculations were performed by a macro within NIH IMAGE (n ϭ 3 to 5 animals per group). A References similar method was used to calculate colocalization of Ang-1 with perfused vessels. To determine the average thickness of the basement membrane as Baluk, P., Morikawa, S., Haskell, A., Mancuso, M., and McDonald, D.M. indicated by collagen IV staining, 4 ϫ 4 grids were superimposed on three (2003) . Abnormalities of basement membrane on blood vessels and endothe-432 ϫ 330 m high-resolution images from 10 m thick sections using lial sprouts in tumors. Am. J. Pathol. 163, 1801-1815. Adobe Photoshop software (n ϭ 3 to 4 animals per group). Wherever grid Benjamin, L.E., Golijanin, D., Itin, A., Pode, D., and Keshet, E. (1999) . Seleclines intersected collagen IV-positive basement membrane structures, their tive ablation of immature blood vessels in established human tumors follows diameter and smallest distance to the lectin signal was measured. vascular endothelial growth factor withdrawal. J. Clin. Invest. 103, 159-165. In situ zymography was performed after the lectin staining of perfused vessels by overnight incubation of unfixed frozen sections with DQ collagen Bottaro, D.P., and Liotta, L.A. (2003) . Cancer: Out of air is not out of action. IV (Molecular Probes), which contains quenched fluorescence that is reNature 423, 593-595. leased after collagen IV degradation.
Brown, E.B., Campbell, R.B., Tsuzuki, Y., Xu, L., Carmeliet, P., Fukumura, To detect basement membrane structures in human brain tumors, a D., and . In vivo measurement of gene expression, angiogentissue microarray containing 30 cases of histologically confirmed glioblastoesis and physiological function in tumors using multiphoton laser scanning mas (2 samples per patient, Petagen) and 2 normal brain samples was microscopy. Nat. Med. 7, 864-868. stained with a rabbit anti-collagen IV antibody and the Envision detection Carmeliet, P., and Jain, R.K. (2000) . Angiogenesis in cancer and other diskit (both DAKO). Basement membrane thickness of tumor vessels was eases. Nature 407, 249-257. scored by an independent observer in comparison to normal brain (thicker/ normal/thinner).
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